Keywords: pfizer, aromasin, boosts, dfs, early, breast, cancer
Pfizer's Aromasin boosts DFS 11% in early breast cancer
Article | 22 December 2008
Pfizer's aromatase inhibitor Aromasin (exemestane) given to women with early breast cancer reduces the relative risk of disease recurrence (measured ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscribe now
for unlimited access to all articles
Subscriptions are £60 per month, pay as you go.
Find out more details.
Already a subscriber? Click here to log in
- Aspen Pharma offers to buy GlaxoSmithKline's thrombosis brands and manufacturing site
- US Supreme Court says patent settlement can "sometimes" be illegal
- Athera and Boehringer Ingelheim enter option agreement on a novel therapy for atherosclerosis
- FDA probes two deaths possibly linked to Lilly's antipsychotic Zyprexa Relprevv
- Australia's pharma industry applauds R&D regulatory reform
